Literature DB >> 19778283

Lack of association between FXIII-Val34Leu, FVII-323 del/ins, and transforming growth factor beta1 (915G/T) gene polymorphisms and bronchopulmonary dysplasia: a single-center study.

Fatma Belgin Ataç1, Deniz Anuk Ince, Hasibe Verdi, Zeynel Gökmen, Ayse Canan Yazici, Hande Gülcan, Aylin Tarcan, Ayse Taneri, Ezgi Sezgin, Namik Ozbek.   

Abstract

Bronchopulmonary dysplasia (BPD) is a multifactorial disease of preterm infants that is characterized by airway injury, inflammation, and parenchymal remodeling. Extravascular fibrin deposits in septae and alveoli due to the altered fibrin turnover are the pathological hallmarks of BPD that strongly indicates the importance of the imbalance in the competing activities of coagulation and fibrinolysis. Activation of the coagulation cascade leads to intraalveolar fibrin deposition in many inflammatory pulmonary disorders. Increased fibrin formation or decreased fibrinolysis may cause extravascular fibrin deposition. We evaluated the association between FXIII-Val34Leu, FVII-323 del/ins, and transforming growth factor beta1 (TGF-beta(1)) (915G/T) gene polymorphisms in patients with BPD. The study group consisted of 98 preterm infants with BPD. Ninety-four of the 192 preterm neonates were without BPD and sampled for the control group. Restriction fragment size analyses were performed by examining digested PCR products for FXIII-Val34Leu, FVII-323 del/ins, and TGF-beta(1) (915G/C) genotypes. No significant associations were found between FXIII-Val34Leu, FVII-323 del/ins, TGF-beta(1) (915G/C) gene polymorphisms and BPD phenotype in our population. Further studies with other genes are required for the identification of molecular predisposing factors for BPD that may help in the development of new treatments and hence might allow for targeting of this treatment to a "high-risk" subgroup, reducing unnecessary exposure to potentially harmful therapies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19778283     DOI: 10.1089/dna.2009.0928

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  4 in total

Review 1.  Genetics of bronchopulmonary dysplasia in the age of genomics.

Authors:  Pascal M Lavoie; Marie-Pierre Dubé
Journal:  Curr Opin Pediatr       Date:  2010-04       Impact factor: 2.856

2.  The role of plasminogen activator inhibitor-1 and angiotensin-converting enzyme gene polymorphisms in bronchopulmonary dysplasia.

Authors:  Deniz Anuk Ince; Fatma Belgin Atac; Servet Ozkiraz; Ugur Dilmen; Hande Gulcan; Aylin Tarcan; Namik Ozbek
Journal:  Genet Test Mol Biomarkers       Date:  2010-09-06

Review 3.  Targeting inflammation to prevent bronchopulmonary dysplasia: can new insights be translated into therapies?

Authors:  Clyde J Wright; Haresh Kirpalani
Journal:  Pediatrics       Date:  2011-06-06       Impact factor: 7.124

Review 4.  Progress in understanding the genetics of bronchopulmonary dysplasia.

Authors:  Gary M Shaw; Hugh M O'Brodovich
Journal:  Semin Perinatol       Date:  2013-04       Impact factor: 3.300

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.